Home / Peptides / Orforglipron
Orforglipron (Foundayo) Dosage: Label Schedule and Status
FDA-approved pill
Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
Also called: Foundayo, LY3502970
Regulatory status (US)
FDA-approved on April 1, 2026 as Foundayo (Eli Lilly) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has no type 2 diabetes indication on the current label.
What it is
An oral, small-molecule GLP-1 receptor agonist taken once a day with no food or water restrictions. It is not a peptide, so there is nothing to reconstitute and no syringe math.
Label dose escalation (Foundayo tablets)
| Step | Daily dose | Note |
|---|---|---|
| 1 | 0.8 mg | At least 30 days |
| 2 | 2.5 mg | At least 30 days |
| 3 | 5.5 mg | May stay here |
| 4 | 9 mg | Maximum with strong CYP3A4 inhibitors |
| 5 | 14.5 mg | |
| 6 | 17.2 mg | Maximum dose |
From the Foundayo prescribing information; at least 30 days at each step. If 7 or more doses in a row are missed, the label says to re-escalate.
What human studies show
- ATTAIN-1: about 12% average weight loss at the highest dose (company-reported).
Safety
- Boxed warning: risk of thyroid C-cell tumors (class warning for GLP-1 drugs).
- Warnings include pancreatitis, severe GI reactions, kidney injury, gallbladder disease and low blood sugar with insulin or sulfonylureas.
Compare
Questions
- Is Orforglipron FDA-approved?
- FDA-approved on April 1, 2026 as Foundayo (Eli Lilly) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has no type 2 diabetes indication on the current label.
- What dose of Orforglipron has been studied?
- 1: 0.8 mg: At least 30 days; 2: 2.5 mg: At least 30 days; 3: 5.5 mg: May stay here; 4: 9 mg: Maximum with strong CYP3A4 inhibitors; 5: 14.5 mg; 6: 17.2 mg: Maximum dose. From the Foundayo prescribing information; at least 30 days at each step. If 7 or more doses in a row are missed, the label says to re-escalate.
Related
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Elamipretide (SS-31)Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Sources
- Foundayo (orforglipron) US prescribing information, Eli Lilly
- Healio: FDA approves orforglipron, an oral GLP-1, for adults with obesity (Apr 2026)
Last checked 2026-11-16. How we pick and check sources: methodology.